Silence Therapeutics Plc Stock Market Value
| SLN Stock | USD 4.45 0.09 1.98% |
| Symbol | Silence |
Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Silence Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Silence Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Silence Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Silence Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Silence Therapeutics PLC or generate 0.0% return on investment in Silence Therapeutics over 90 days. Silence Therapeutics is related to or competes with Contineum Therapeutics, Amarin PLC, Kyverna Therapeutics, Aldeyra, Capricor Therapeutics, Lexeo Therapeutics, and Lyell Immunopharma. Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid th... More
Silence Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Silence Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Silence Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 23.8 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 6.88 |
Silence Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silence Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Silence Therapeutics' standard deviation. In reality, there are many statistical measures that can use Silence Therapeutics historical prices to predict the future Silence Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.77) | |||
| Treynor Ratio | (0.91) |
Silence Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.90) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (932.35) | |||
| Standard Deviation | 4.2 | |||
| Variance | 17.64 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.77) | |||
| Treynor Ratio | (0.91) | |||
| Maximum Drawdown | 23.8 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 6.88 | |||
| Skewness | 0.2852 | |||
| Kurtosis | 1.4 |
Silence Therapeutics PLC Backtested Returns
Silence Therapeutics PLC owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.14, which indicates the firm had a -0.14 % return per unit of risk over the last 3 months. Silence Therapeutics PLC exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Silence Therapeutics' Coefficient Of Variation of (932.35), variance of 17.64, and Risk Adjusted Performance of (0.08) to confirm the risk estimate we provide. The entity has a beta of 0.51, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Silence Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Silence Therapeutics is expected to be smaller as well. At this point, Silence Therapeutics PLC has a negative expected return of -0.59%. Please make sure to validate Silence Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Silence Therapeutics PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.52 |
Modest predictability
Silence Therapeutics PLC has modest predictability. Overlapping area represents the amount of predictability between Silence Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Silence Therapeutics PLC price movement. The serial correlation of 0.52 indicates that about 52.0% of current Silence Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.52 | |
| Spearman Rank Test | 0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 0.33 |
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Silence Stock
Moving against Silence Stock
| 0.88 | DRTS | Alpha Tau Medical | PairCorr |
| 0.86 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.68 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.68 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.68 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Silence Therapeutics Correlation, Silence Therapeutics Volatility and Silence Therapeutics Performance module to complement your research on Silence Therapeutics. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Silence Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.